Skip to content
MARKETS / NYSE / STE
NYSE · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · LARGE CAP

Steris PLC STE

10 fiscal years on record · USD · FY2025 reported · SEC filings only
9 YEARS OF DIVIDEND GROWTH
$5.9B
▲ 8.7% YoY
$782.3M
▲ 27.3% YoY
$972.4M
▲ 25.0% YoY
In brief

What this company does

STERIS is a global provider of products and services that support patient care with an emphasis on infection prevention. It offers consumable products such as detergents, endoscopy accessories, barrier products, instruments and tools; services including equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair, laboratory testing, and outsourced reprocessing; capital equipment such as sterilizers, surgical tables, and automated endoscope reprocessors; and connectivity solutions such as operating room integration. During fiscal 2026, the company averaged approximately 18,000 employees throughout the world. STERIS operates and reports its financial information in three reportable business segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment provides an offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. The Life Sciences segment provides an offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, in particular those focused on aseptic manufacturing.

Written from the business description in STERIS plc's annual report to the U.S. Securities and Exchange Commission, filed 29 May 2026. Every sentence was checked against that document before publication.

Growth
USD 5.9B
Revenue, FY2025 · full 10-year series below
Revenue $B Net income $B
FY2025 · Revenue 5.9 · Net income 0.8
2B4B2016201720182019202020212022202320242025
Compound annual growth
+9.4%
+13.8%
+94.1%
+14.5%
+95.0%
+11.4%
+10.2%
+9.4%
−3.2%
+27.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +13.8% a year over five years — but profit grew faster: net income at +14.5%, earnings per share at +11.4%.

The share count rose from 0.09B to 0.10B over the period.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
13 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 18.6% · Net 13.2%
5%10%15%2016201720182019202020212022202320242025
ROE
FY2025 · ROE 11.3%
5%10%2016201720182019202020212022202320242025

Each USD of equity produced 11 cents of profit this year.

Cash & shareholders
USD 444.4M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 972.4
400M800M2016201720182019202020212022202320242025
Net buybacks $M Dividends $M
FY2025 · Dividends 241.8 · Net buybacks 202.6
200M400MDividendsNet buybacks2016201720182019202020212022202320242025

USD 241.8M in dividends and USD 202.6M in buybacks — 57% of the year's profit went back to shareholders.

Total assetsUSD 10.7B
EquityUSD 7.2B
CashUSD 439.6M
Gross debtUSD 1.9B
Net debtUSD 1.5B
Current ratio2.09×

Net debt stands at 21% of equity.

The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 2025202420232022202120202019201820172016
Revenue $B5.95.55.14.54.23.13.02.82.62.6
Operating income $B1.10.90.80.80.50.50.50.40.40.2
EBITDA $B1.61.31.41.31.00.80.70.60.60.4
Income tax $B0.30.20.10.10.10.10.10.10.10.1
Net income $B0.80.60.40.10.20.40.40.30.30.1
Free cash flow $B1.00.80.60.40.40.50.40.30.30.3
EPS, diluted $7.936.203.811.072.484.634.763.553.391.28
Dividend / sh $2.462.232.031.841.691.571.451.331.211.09
Payout %313653171673430373585
ROE %11.39.56.11.74.710.912.49.59.1·
Shares out B0.100.100.100.100.100.090.080.080.08·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 48 reconciliationsAUDITED

Reconciled in 10 of 19 fiscal years. 47 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityOrthopedic, Prosthetic & Surgical Appliances & Supplies
Listed onNYSE
Incorporated inoutside the United States — SEC code L2
Fiscal year endsMarch 31
Data on record since2016

Share this section

Download image